ArticleCurrent medicinal chemistry2025
Identification and Functional Characterization of Essential Genes Related to Gefitinib Sensitivity in Lung Adenocarcinoma.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance.Frontiers in cell and developmental biology · 2026Article
- Profiling the Complexity of Resistance Factors in Cancer Cells Towards Berberine and Its Derivatives.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Molecular cargo of small EVs from NSCLC patient BALF and plasma: unveiling their role in airway inflammation and immune regulation in a novel human 3D bronchial model.Cell communication and signaling : CCS · 2025Article
- Phosphofructokinase-1 redefined: a metabolic hub orchestrating cancer hallmarks through multi-dimensional control networks.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to determine the molecular markers related to gefitinib sensitivity for guiding the prognosis of lung adenocarcinoma (LUAD) and providing new evidence for promoting the precise treatment of LUAD.
backgroundLung adenocarcinoma (LUAD) is a prevalent lung cancer subtype with inferior survival outcomes. However, gefitinib is the first molecular targeted drug approved by Food and Drug Administration (FDA) to treat advanced LUAD. Gefitinib sensitivity-related gene targets for LUAD are rarely studied.
objectiveThis study was designed to probe the potential molecular markers related to the sensitivity of gefitinib in LUAD.
methodsThe gene expression profiles of LUAD cells in the Genomics of Drug Sensitivity in Cancer (GDSC) database were used for Weighted Gene Co-expression Network Analysis (WGCNA) to select the modules most related to gefitinib sensitivity. The Cancer Genome Atlas (TCGA) database was used to compare the expression of LUAD and para-cancerous tissues. Differentially expressed genes (DEGs) were then filtered and intersected with the highly linked genes in the module relevant to gefitinib sensitivity. Univariate Cox regression analysis was conducted to identify prognostically related genes to LUAD. The correlation between genes and drug IC50 was calculated by Spearman correlation analysis. Quantitative RT-PCR and immunofluorescence detection validated hub genes FAM13B and PFKP expressions.
resultsAmong the 10 modules divided by WGCNA, the module with the most significant positive correlation and the most significant negative correlation with gefitinib sensitivity were found. FAM13B, PFKP, FGD3, RNASE1, MUC16, GJB5, and GJB3 were hub genes related to gefitinib sensitivity in LUAD. Significantly, the low expressed FAM13 in LUAD tissues positively correlated with immune response. At the same time, overexpressed PFKP in the LUAD cohort was related to an unfavorable prognosis, cell proliferation, and cell cycle. We also found that FAM13B and PFKP expressions were enhanced in LUAD cell lines.
conclusionsThis study identified 7 critical genes related to gefitinib sensitivity in LUAD. Functionally, genes positively correlated with gefitinib sensitivity might regulate the progression of LUAD through the immune, cell cycle, and metabolic pathways and showed potential effects in predicting sensitivity to different drugs. These findings help offer a theoretical direction for personalized treatment of LUAD.
Indexed as
Identifiers
38584557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.